Literature DB >> 2288835

Lack of effect of co-trimoxazole on the pharmacokinetics and pharmacodynamics of nifedipine.

C Edwards1, S Monkman, S Cholerton, M D Rawlins, J R Idle, R E Ferner.   

Abstract

The pharmacokinetics of nifedipine and its primary oxidised metabolite, M-I were studied in nine healthy volunteers following a single oral dose of 20 mg nifedipine alone or after pretreatment with oral co-trimoxazole. Following pretreatment with co-trimoxazole, no significant effect was detected on maximum plasma concentration, elimination half-life, or area under the plasma concentration-time curve of either nifedipine or M-I, nor on the blood pressure response to nifedipine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2288835      PMCID: PMC1368311          DOI: 10.1111/j.1365-2125.1990.tb05456.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Determination of nifedipine and its three principal metabolites in plasma and urine by automated electron-capture capillary gas chromatography.

Authors:  B J Schmid; H E Perry; J R Idle
Journal:  J Chromatogr       Date:  1988-03-04

2.  Interaction between warfarin and sulphamethoxazole.

Authors:  W J Tilstone; J M Gray; R H Nimmo-Smith; D H Lawson
Journal:  Postgrad Med J       Date:  1977-07       Impact factor: 2.401

3.  Nephrotoxicity by co-trimoxazole and cyclosporin in transplanted patients.

Authors:  O Ringdén; P Myrenfors; G Klintmalm; G Tydén; L Ost
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

4.  Nephrotoxicity of trimethoprim and cotrimoxazole in renal allograft recipients treated with cyclosporine.

Authors:  J F Thompson; D H Chalmers; A G Hunnisett; R F Wood; P J Morris
Journal:  Transplantation       Date:  1983-08       Impact factor: 4.939

5.  Letter: Potentiation of warfarin by co-trimoxazole.

Authors:  C Hassall; C L Feetam; R H Leach; M J Meynell
Journal:  Lancet       Date:  1975-12-06       Impact factor: 79.321

6.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.

Authors:  T Aoyama; S Yamano; D J Waxman; D P Lapenson; U A Meyer; V Fischer; R Tyndale; T Inaba; W Kalow; H V Gelboin
Journal:  J Biol Chem       Date:  1989-06-25       Impact factor: 5.157

7.  Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase.

Authors:  F J Gonzalez; B J Schmid; M Umeno; O W Mcbride; J P Hardwick; U A Meyer; H V Gelboin; J R Idle
Journal:  DNA       Date:  1988-03

8.  Ranitidine and cimetidine; drug interactions with single dose and steady-state nifedipine administration.

Authors:  S R Smith; M J Kendall; J Lobo; A Beerahee; D B Jack; M R Wilkins
Journal:  Br J Clin Pharmacol       Date:  1987-03       Impact factor: 4.335

9.  Racemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.

Authors:  R A O'Reilly; C H Motley
Journal:  Ann Intern Med       Date:  1979-07       Impact factor: 25.391

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.